Action A115450 HLB THERAPEUTICS CO.,LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues HLB Therapeutics Co.,Ltd.

Actions

A115450

KR7115450009

Cours en clôture Korea S.E.
Autres places de cotation
 00:00:00 10/05/2024 		Varia. 5j. Varia. 1 janv.
9 340 KRW -5,56% Graphique intraday de HLB Therapeutics Co.,Ltd. -11,89% +113,00%
18/03 HLB Therapeutics Co. publie ses résultats pour l'exercice clos le 31 décembre 2023 CI
2023 HLB Therapeutics Co. présente ses résultats pour le troisième trimestre et les neuf mois se terminant le 30 septembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
HLB Therapeutics Co.,Ltd. announced that it has received KRW 29.99999658 billion in funding from HLB Co., Ltd.
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
HLB Life Science Co., Ltd. announced that it has received KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.
HLB Life Science Co., Ltd. announced that it expects to receive KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.
Panagene Inc. announced that it expects to receive KRW 56.599994061 billion in funding from a group of investors
Panagene Inc. announced that it expects to receive KRW 46.068324061 billion in funding from HLB Co., Ltd., HLB Investment Co., Ltd., HLB bioStep Co.,Ltd., HLB innoVation Co.,Ltd., HLB Therapeutics Co.,Ltd.
HLB Therapeutics Co.,Ltd. announced that it has received KRW 2.5 billion in funding
HLB Therapeutics Co.,Ltd. announced that it has received KRW 5 billion in funding
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259
HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors
Oblato, Inc. announced that it has received KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.
Oblato, Inc. announced that it expects to receive KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd.
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors
HLB Therapeutics Co.,Ltd. announced that it has received KRW 13.0088 billion in funding from HLB Co., Ltd.
HLB Therapeutics to Raise 13 Billion Won via Stock Sale
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 13.0088 billion in funding from HLB Co., Ltd.
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action A115450
  4. Actualités HLB Therapeutics Co.,Ltd.
  5. Autres langues